GlassScriptPhysician profile
Eric B Dybbro
NPI 1942696463
$5,098.61
in general payments reported to CMS, 2019-2025
11 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 86% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2023: $352 · 2024: $2,449 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,070 · Consulting Fee: $1,625 · Food and Beverage: $1,196 · Education: $23.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,070.00 |
| Consulting Fee | $1,625.00 |
| Food and Beverage | $1,195.73 |
| Education | $23.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,460.81 | 2024-2025 | Bylvay |
| Mirum Pharmaceuticals, INC. | $2,084.98 | 2023-2025 | Ctexli, Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $123.88 | 2022-2025 | Livtencity |
| Roche Diagnostics Corporation | $120.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $111.34 | 2023 | Dupixent |
| Abbvie INC. | $97.50 | 2025 | |
| Alcresta Therapeutics, INC. | $26.69 | 2024 | Relizorb |
| Travere Therapeutics, INC. | $23.93 | 2022-2023 | Cholbam |
| Orphalan INC | $20.71 | 2023 | Cuvrior |
| Albireo Pharma, INC. | $15.11 | 2023 | Bylvay |
| Qol Medical, LLC | $12.89 | 2023 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dybbro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.